TREATMENT OF LUNG CONDITIONS WITH INTEGRIN SUBUNIT ALPHA 1 (ITGA1) INHIBITORS

The present disclosure provides methods of treating subjects having a lung disease such as a fibrotic lung disease, pulmonary fibrosis, interstitial lung disease, chronic obstructive pulmonary disease (COPD), or asthma, or at risk of developing a lung disease, and methods of identifying subjects hav...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	BARAS Aris, FERREIRA Manuel Allen Revez, ABECASIS Goncalo, HOROWITZ Julie, E, SIMINOVITCH Katherine, SUCIU Maria Cristina
Format:	Patent
Sprache:	eng ; spa
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure provides methods of treating subjects having a lung disease such as a fibrotic lung disease, pulmonary fibrosis, interstitial lung disease, chronic obstructive pulmonary disease (COPD), or asthma, or at risk of developing a lung disease, and methods of identifying subjects having an increased risk of developing a lung disease. La presente descripción proporciona métodos para el tratamiento de sujetos que tienen una enfermedad pulmonar, tal como una enfermedad pulmonar fibrótica, fibrosis pulmonar, enfermedad pulmonar intersticial, enfermedad pulmonar obstructiva crónica (EPOC) o asma, o se encuentra en riesgo de desarrollar una enfermedad pulmonar, y métodos para identificar sujetos que tienen un mayor riesgo de desarrollar una enfermedad pulmonar.